Table of Contents Table of Contents 3 List of Tables 5 List of Figures 5 Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6 Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7 Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8 Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9 Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10 Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12 Asset Purchase 12 Eiger BioPharma Acquires Assets and Rights to exendin 9-39 from Tracey McLaughlin and Colleen Craig 12 Venture Financing 13 Eiger BioPharma Raises USD3 Million in Venture Financing 13 Celladon Raises USD3 Million in Venture Financing 14 Eiger BioPharma Raises USD6 Million in Venture Financing 15 Eiger Biopharma Raises US$1 Million In Third Tranche Of Series A Financing 16 Partnerships 17 Eiger BioPharma Enters into Collaboration Agreement with Progeria Research 17 Merger 18 Eiger BioPharma Merges with Celladon 18 Licensing Agreements 20 Eiger BioPharmaceuticals Enters into Licensing Agreement with Bristol-Myers Squibb 20 Eiger BioPharma Enters into Licensing Agreement with Stanford University for Post-Bariatric Surgical Hypoglycemia 21 Eiger BioPharma Enters into Licensing Agreement with Stanford University 22 Eiger BioPharma Enters into Licensing Agreement with Stanford University for Pulmonary Arterial Hypertension 23 Eiger BioPharma Enters into Licensing Agreement with Nippon Kayaku 24 Eiger BioPharma Enters into Licensing Agreement with Janssen Pharma for Tipifarnib 25 Equity Offering 26 Eiger BioPharma Prices Public Offering of Shares for USD40 Million 26 Eiger BioPharma Raises USD18.5 Million in Public Offering of Shares 28 Eiger BioPharma Raises USD20 Million in Public Offering of Shares 30 Eiger BioPharma Plans to Raise up to USD25 Million in Public Offering of Shares 32 Eiger BioPharma Raises USD39.5 Million in Private Placement of Shares 33 Asset Transactions 35 Eiger BioPharma Sells Mydicar to Theragene Pharma 35 Eiger BioPharmaceuticals Inc - Key Competitors 36 Eiger BioPharmaceuticals Inc - Key Employees 37 Eiger BioPharmaceuticals Inc - Locations And Subsidiaries 38 Head Office 38 Other Locations & Subsidiaries 38 Recent Developments 39 Financial Announcements 39 Aug 10, 2018: Eiger Biopharmaceuticals announces second quarter 2018 financial results 39 May 11, 2018: Eiger BioPharmaceuticals Reports First Quarter 2018 Financial Results 40 Mar 12, 2018: Eiger BioPharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results 41 Nov 09, 2017: Eiger BioPharmaceuticals Reports Third Quarter 2017 Financial Results 42 Aug 14, 2017: Eiger BioPharmaceuticals Reports Second Quarter 2017 Financial Results 44 May 12, 2017: Eiger BioPharmaceuticals Reports First Quarter 2017 Financial Results 45 Mar 23, 2017: Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results 47 Corporate Communications 49 Jan 08, 2018: Eiger BioPharmaceuticals Announces Appointment of Commercial Operations Industry Veteran Eldon Mayer to its Board of Directors 49 Jan 03, 2018: Eiger BioPharmaceuticals Appoints David Apelian, MD, PhD, MBA Chief Operating Officer and Executive Medical Officer 50 Sep 18, 2017: Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of Directors 51 Jun 14, 2017: Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors 52 Apr 18, 2017: Eiger BioPharmaceuticals appoints new lead for development of PBH treatment 53 Product News 54 04/18/2017: Eiger Announces Industry Veteran Lisa Porter, M.D. to Lead Development of Exendin 9-39 for the Treatment of Post-Bariatric Hypoglycemia 54 Product Approvals 55 Sep 05, 2017: Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection 55 Jul 27, 2017: Eiger Announces FDA Fast Track Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection 56 May 03, 2017: Eiger Announces U.S. IND Filing of Pegylated Interferon Lambda for Hepatitis Delta Virus Infection – LIMT HDV: Lambda Interferon MonoTherapy in HDV Study Enrolling 57 Clinical Trials 58 Aug 14, 2018: Eiger BioPharmaceuticals completes enrolment in Prevent trial 58 Mar 26, 2018: Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia 59 Oct 23, 2017: Eiger Announces Positive Phase 2 Interim 24-Week Data with Pegylated Interferon Lambda in Hepatitis Delta Virus Infection at the American Association for the Study of Liver Diseases Meeting 60 Oct 02, 2017: Eiger Announces Presentation on Lambda at the American Association for the Study of Liver Diseases Meeting 61 Jul 24, 2017: Eiger Completes Enrollment in Phase 2 LIMT HDV Study of Pegylated Interferon Lambda in Hepatitis Delta Virus Infection 62 Jun 12, 2017: Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San Diego 63 Jun 06, 2017: Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients 65 Appendix 66 Methodology 66 About 66 Contact Us 66 Disclaimer 66

List of Tables Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2 Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6 Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7 Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8 Eiger BioPharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9 Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10 Eiger BioPharma Acquires Assets and Rights to exendin 9-39 from Tracey McLaughlin and Colleen Craig 12 Eiger BioPharma Raises USD3 Million in Venture Financing 13 Celladon Raises USD3 Million in Venture Financing 14 Eiger BioPharma Raises USD6 Million in Venture Financing 15 Eiger Biopharma Raises US$1 Million In Third Tranche Of Series A Financing 16 Eiger BioPharma Enters into Collaboration Agreement with Progeria Research 17 Eiger BioPharma Merges with Celladon 18 Eiger BioPharmaceuticals Enters into Licensing Agreement with Bristol-Myers Squibb 20 Eiger BioPharma Enters into Licensing Agreement with Stanford University for Post-Bariatric Surgical Hypoglycemia 21 Eiger BioPharma Enters into Licensing Agreement with Stanford University 22 Eiger BioPharma Enters into Licensing Agreement with Stanford University for Pulmonary Arterial Hypertension 23 Eiger BioPharma Enters into Licensing Agreement with Nippon Kayaku 24 Eiger BioPharma Enters into Licensing Agreement with Janssen Pharma for Tipifarnib 25 Eiger BioPharma Prices Public Offering of Shares for USD40 Million 26 Eiger BioPharma Raises USD18.5 Million in Public Offering of Shares 28 Eiger BioPharma Raises USD20 Million in Public Offering of Shares 30 Eiger BioPharma Plans to Raise up to USD25 Million in Public Offering of Shares 32 Eiger BioPharma Raises USD39.5 Million in Private Placement of Shares 33 Eiger BioPharma Sells Mydicar to Theragene Pharma 35 Eiger BioPharmaceuticals Inc, Key Competitors 36 Eiger BioPharmaceuticals Inc, Key Employees 37 Eiger BioPharmaceuticals Inc, Subsidiaries 38List of Figures Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2 Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2 Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2 Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2 Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6 Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7 Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8 Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9